- Home
- TIRX vs BCDA Comparison
TIRX vs BCDA Comparison
Compare TIRX & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIRX
- BCDA
- Stock Information
- Founded
- TIRX 2010
- BCDA N/A
- Country
- TIRX China
- BCDA United States
- Employees
- TIRX N/A
- BCDA N/A
- Industry
- TIRX Specialty Insurers
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- TIRX Finance
- BCDA Health Care
- Exchange
- TIRX Nasdaq
- BCDA Nasdaq
- Market Cap
- TIRX 12.0M
- BCDA 10.1M
- IPO Year
- TIRX 2021
- BCDA N/A
- Fundamental
- Price
- TIRX $1.20
- BCDA $2.39
- Analyst Decision
- TIRX
- BCDA Strong Buy
- Analyst Count
- TIRX 0
- BCDA 1
- Target Price
- TIRX N/A
- BCDA $25.00
- AVG Volume (30 Days)
- TIRX 69.4K
- BCDA 230.7K
- Earning Date
- TIRX 08-15-2025
- BCDA 08-12-2025
- Dividend Yield
- TIRX N/A
- BCDA N/A
- EPS Growth
- TIRX N/A
- BCDA N/A
- EPS
- TIRX N/A
- BCDA N/A
- Revenue
- TIRX $3,219,336.00
- BCDA $3,000.00
- Revenue This Year
- TIRX N/A
- BCDA N/A
- Revenue Next Year
- TIRX N/A
- BCDA N/A
- P/E Ratio
- TIRX N/A
- BCDA N/A
- Revenue Growth
- TIRX 158.74
- BCDA N/A
- 52 Week Low
- TIRX $1.07
- BCDA $1.63
- 52 Week High
- TIRX $4.15
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- TIRX 42.86
- BCDA 58.67
- Support Level
- TIRX $1.15
- BCDA $1.98
- Resistance Level
- TIRX $1.29
- BCDA $2.45
- Average True Range (ATR)
- TIRX 0.07
- BCDA 0.17
- MACD
- TIRX 0.00
- BCDA 0.04
- Stochastic Oscillator
- TIRX 20.31
- BCDA 88.00
About TIRX TIAN RUIXIANG Holdings Ltd
Tian Ruixiang Holdings Ltd is an Insurance Brokerage firm. It distributes a wide range of insurance products, which are categorized into two groups; property and casualty insurance, such as commercial property insurance, liability insurance, accidental insurance, and automobile insurance; and other insurances, such as health insurance, life insurance, and miscellaneous insurances. It also generates a small amount of revenue from risk management services. The firm act on behalf of its customers seeking insurance coverage from insurance companies. It generates revenue from the provision of insurance brokerage services.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).